Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis

Patients with triple-negative breast cancer (TNBC) who relapse early after (neo)adjuvant chemotherapy have more aggressive disease. In the ASCENT trial, sacituzumab govitecan (SG), an antibody-drug conjugate composed of an anti-Trop–2 antibody coupled to SN-38 via a hydrolyzable linker, improved out...

Descripción completa

Detalles Bibliográficos
Autores principales: Carey, Lisa A., Loirat, Delphine, Punie, Kevin, Bardia, Aditya, Diéras, Véronique, Dalenc, Florence, Diamond, Jennifer R., Fontaine, Christel, Wang, Grace, Rugo, Hope S., Hurvitz, Sara A., Kalinsky, Kevin, O’Shaughnessy, Joyce, Loibl, Sibylle, Gianni, Luca, Piccart, Martine, Zhu, Yanni, Delaney, Rosemary, Phan, See, Cortés, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184615/
https://www.ncbi.nlm.nih.gov/pubmed/35680967
http://dx.doi.org/10.1038/s41523-022-00439-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184615/
https://www.ncbi.nlm.nih.gov/pubmed/35680967
http://dx.doi.org/10.1038/s41523-022-00439-5

Ejemplares similares